Advertisement

Picture EBD Group Cell & Gene Exchange 2017 Washington DC USA May 600x60px
Document › Details

Sequenom, Inc.. (5/30/14). "Press Release: Sequenom, Inc. Reports Sales of Bioscience Business". San Diego, CA.

Organisations Organisation Sequenom Inc. (Nasdaq: SQNM)
  Group LabCorp (Group)
  Organisation 2 Agena Bioscience Inc.
  Group Agena Bioscience (Group)
Products Product MassARRAY® system
  Product 2 private equity
Index terms Index term Agena Bioscience–Sequenom: MassArray technology, 201405 acquisition $31.8m + $4m milestones of Sequenom bioscience business by Agena
  Index term 2 Agena Bioscience–Telegraph Hill Partners: investment, 201405 existent Ageno is portfolio company of Telegraph Hill Partners
Person Person Hixson, Harry F., jr.(Sequenom 201008 CEO before PsychoGenics 200507)
     


Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that it has completed the sale of its Bioscience business to Agena Bioscience, a portfolio company of Telegraph Hill Partners.

The terms of the agreement provide for a purchase price of $31.8 million, subject to certain adjustments, and Sequenom may also receive up to $4 million in contingent consideration upon the achievement of certain regulatory and sales milestones. Agena Bioscience also assumed certain liabilities related to the Bioscience business, which does not include any portion of Sequenom's bank debt or convertible notes outstanding. The facility lease for its Bioscience location in San Diego was also assumed by Agena Bioscience. All of the current Bioscience employees will be offered employment by Agena Bioscience.

"We are pleased to sell the business to Agena Bioscience and Telegraph Hill Partners as they plan to invest in the growth of the Bioscience business to achieve its full potential. This sale strengthens our balance sheet, and will enable us to focus exclusively on our Sequenom Laboratories business as we work toward achieving profitability," said Harry F. Hixson, Jr., Chairman and CEO of Sequenom.

The acquired business will continue to manufacture and sell the MassARRAY® System, a proprietary mass spectrometry-based genetic analysis instrument and associated products and services that provide research and clinical investigators with economical high multiplexing, high volume results, and precise quantification in a well-established platform technology. The UltraSEEK™ chemistry, used on the MassARRAY System, will be featured at the American Society of Clinical Oncology annual meeting in Chicago, May 30 - June 3, 2014. UltraSEEK enables ultrasensitive somatic mutation detection in plasma at

Jefferies LLC acted as exclusive financial advisor to Sequenom in connection with this transaction.


About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genomic and genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve molecular diagnostic markets. Website: http://www.sequenom.com/.


Forward-Looking Statements

Except for the historical information contained herein, the matters set forth in this press release, including statements regarding the Company's potential to receive contingent consideration in connection with the achievement of certain regulatory and sales milestones, future offers of employment, the expected activities of the acquired business and the plans of the new owners, the Company's expectations and ability to focus exclusively on its Sequenom Laboratories business and work towards achieving profitability, and the Company's commitment to improving healthcare through revolutionary genomic and genetic analysis solutions, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with the Company's reliance on the buyer to achieve the regulatory and sales milestones, market demand for and acceptance and use of the Company's technology and laboratory developed tests, reliance upon the collaborative efforts of other parties such as, without limitation, healthcare providers, international distributors and licensees, the Company or third parties obtaining or maintaining regulatory approvals that impact the Company's business, government regulation particularly with respect to diagnostic products and laboratory developed tests, publication processes, the performance of designed product enhancements, the Company's ability to develop and commercialize technologies and products, particularly new technologies such as noninvasive prenatal diagnostics, laboratory developed tests, the Company's financial position, the timing and amount of reimbursement that Sequenom Laboratories receives from payors for its laboratory developed tests, the Company's ability to manage its existing cash resources or raise additional cash resources, competition, intellectual property protection and intellectual property rights of others, litigation involving the Company, and other risks detailed from time to time in the Company's most recently filed reports on Form 8-K, and its most recently filed Annual Report on Form 10-K/A and 10-K for the year ended December 31, 2013, and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

   
Record changed: 2016-03-20

Advertisement

Picture Fairtec GmbH We Optimise the ROI of Your Event 600x60px

More documents for LabCorp (Group)


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

Picture EBD Group Cell & Gene Exchange 2017 Washington DC USA May 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Cell & Gene Exchange 2017 Washington DC USA May 120x180px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px